Tomorrow it will $FRE (-1,33 %) will publish its figures for the past quarter tomorrow. Analysts and investors will be focusing primarily on sales and earnings per share, as both key figures should show whether the ongoing restructuring and turnaround process is bearing fruit. According to current consensus data, the market expects:
Sales (expected): EUR 5.86bn
EPS (expected): EUR 0.91
What I will pay particular attention to:
- Operational stability: $FRE (-1,33 %) operates in several segments (Kabi, Helios, Vamed, etc.), which offers diversification on the one hand, but also shows that individual areas perform differently. The focus is therefore on organic sales growth and improved margins, particularly in the clinical business.
- Cost management & efficiency: In recent years, the company has implemented structural programmes and portfolio adjustments, among other things, in order to increase profitability and stabilize earnings. Accordingly, I will pay attention to how these measures are working in the current quarter.
- Cash flow & balance sheet: Especially in a capital-intensive healthcare environment, the development of free cash flow and debt remains an issue, as these have an impact on investments and the ability to pay dividends.
An additional strategic signal comes from the early extension of CEO Michael Sen's contract until 2031, which is attracting attention today. This personnel decision can be seen as a signal of continuity and confidence in the ongoing restructuring and growth course, especially at a time when many stakeholders are looking for clear management decisions.
How do you assess the current upheaval at $FRE (-1,33 %) ? Do you believe that the measures taken in the current quarter will lead to clear progress, or are some risks not yet sufficiently priced in?
~ No investment advice ~
